Krystal Biotech (KRYS) Common Equity (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Common Equity data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 29.66% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 29.66% YoY), and the FY2025 full-year result was $1.2 billion, up 28.87% from the prior year.
• Common Equity rose to $1.3 billion in Q1 2026, from $1.2 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.3 billion in Q1 2026 to a low of $489.6 million in Q1 2023.
• A 5-year average of $822.2 million and a median of $799.2 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity retreated 12.02% in 2022 and soared 63.26% in 2024, its largest moves.
• Tracing KRYS's Common Equity over 5 years: stood at $522.2 million in 2022, then soared by 49.1% to $778.6 million in 2023, then climbed by 21.54% to $946.4 million in 2024, then rose by 28.87% to $1.2 billion in 2025, then advanced by 4.69% to $1.3 billion in 2026.
• Business Quant data shows KRYS's Common Equity at $1.3 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.